Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.
Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s.
In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product also benefits from NCE exclusivity until 2024 – it will be marketed as Accrufer®.
We also have an exclusive licence agreement with ASK Pharm, who will lead development and commercialisation in China.
Find out moreThe content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.
RT @VoxPodcast: On the @VOXmarkets podcast today, Tim Watts, CEO of Shield Therapeutics #STX @ShieldTx explains the headline results from t…
RT @AndrewScottTV: #STX @ShieldTx Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive of ongoing discussions htt…
RT @proactive_UK: $STX Shield Therapeutics CEO says reanalysis of key study has shown Feraccru to be 'credible alternative' https://t.co/AK…
